# Wuxi Shenrui Bio-Pharmaceuticals Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wuxi-shenrui-bio-pharmaceuticals-co

- Industry: Medical Devices & Equipment
- Headquarters: Wuxi, China
- Website: www.sr-bio.com
- Latest round: Series A (Mar 14, 2014)
- Investors on record: 1

## About

Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd, based in Wuxi, China, specializes in precision medicine and in-vitro diagnostics, focusing on the development and production of diagnostic reagents.Founded in 1999, Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd develops diagnostics for healthcare institutions and laboratories. It has made strategic pivots in its offerings, including multiple patents and collaborations with research entities. The company is headquartered in Wuxi, China, and has engaged in investment rounds, including its most recent Series A funding in March 2014 from CDH Investments, marking a total of one significant deal in its portfolio.Wuxi Shenrui Biological Products Co., Ltd. specializes in developing and producing diagnostic reagents within the precision medicine and in-vitro diagnostic sectors. Their offerings include test kits for detecting antibodies related to phospholipase A2 receptor IgG and IgG4, utilizing time-resolved fluorescence immunoassay techniques. These products support high-throughput screening for high-risk HPV types, catering to healthcare institutions, laboratories, and medical research organizations, both domestically and internationally. The company has built a reputation for innovation, supported by numerous patents and collaborations.The revenue model of Wuxi Shenrui Biological Products Co., Ltd. is primarily based on B2B transactions, selling diagnostic reagents to hospitals, diagnostic laboratories, and medical institutions. Their key products, like the phospholipase A2 receptor antibody detection kits, are available for purchase as single units or in bulk, with contracts reflecting the volume and technology involved. Collaborations with research organizations and public health institutions further diversify revenue channels, enhancing their diagnostic solutions in broader healthcare initiatives.Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. is focusing on launching new diagnostic products aimed at enhancing precision medicine capabilities. The company plans to expand its market reach into regions such as Southeast Asia and Europe by 2025. The funds raised during the Series A round in March 2014 will support these product development initiatives and facilitate entry into new markets, strengthening their position in the competitive diagnostics landscape.

## Funding rounds

- Series A, Mar 14, 2014 — CDH Investments

## Investors

- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series A